Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
7.77 (1y: +8%)
Market Cap 729.97 M P/E(ttm)
Enterprise Value 585.59 M P/B 8.63
ACHN- NAS (USA)
Achillion Pharmaceuticals, Inc.
Not Rated
Top Ranked Predictable Companies
$7.77
Switch to:

GuruFocus Financial Strength Rank measures how strong a companyย’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry		 vs
history
Cash to Debt 93.845
ACHN's Cash to Debt is ranked lower than
52% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ACHN: 93.845 )
ACHN' s 10-Year Cash to Debt Range
Min: 1.1   Max: 144.77
Current: 93.85
1.1
144.77
Equity to Asset 0.884
ACHN's Equity to Asset is ranked higher than
88% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 0.54 vs. ACHN: 0.884 )
ACHN' s 10-Year Equity to Asset Range
Min: -6.98   Max: 0.88
Current: 0.88
-6.98
0.88
Interest Coverage No Debt
ACHN's Interest Coverage is ranked higher than
81% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ACHN: No Debt )
ACHN' s 10-Year Interest Coverage Range
Min: No Debt   Max: No Debt
Current: No Debt
Z-Score: 41.55
M-Score: 35.46
GuruFocus Profitability Rank ranks how profitable a company is and how likely the companyย’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
ย•ย•3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rankย•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry		 vs
history
Operating margin (%) -1814.10
ACHN's Operating margin (%) is ranked lower than
66% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -52.55 vs. ACHN: -1814.10 )
ACHN' s 10-Year Operating margin (%) Range
Min: -17954.3   Max: 11935.9
Current: -1814.1
-17954.3
11935.9
Net-margin (%) -1807.7
ACHN's Net-margin (%) is ranked lower than
66% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -55.70 vs. ACHN: -1807.7 )
ACHN' s 10-Year Net-margin (%) Range
Min: -17897.2   Max: 12030.3
Current: -1807.7
-17897.2
12030.3
ROE (%) -65.4
ACHN's ROE (%) is ranked lower than
56% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -16.60 vs. ACHN: -65.4 )
ACHN' s 10-Year ROE (%) Range
Min: -2537.4   Max: -50.4
Current: -65.4
-2537.4
-50.4
ROA (%) -57.8
ACHN's ROA (%) is ranked lower than
65% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -14.40 vs. ACHN: -57.8 )
ACHN' s 10-Year ROA (%) Range
Min: -222.2   Max: -35.9
Current: -57.8
-222.2
-35.9
EBITDA Growth (%) -9.3
ACHN's EBITDA Growth (%) is ranked higher than
69% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -11.35 vs. ACHN: -9.3 )
ACHN' s 10-Year EBITDA Growth (%) Range
Min: -51.7   Max: -9.3
Current: -9.3
-51.7
-9.3
EPS Growth (%) -10.1
ACHN's EPS Growth (%) is ranked higher than
68% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -8.70 vs. ACHN: -10.1 )
ACHN' s 10-Year EPS Growth (%) Range
Min: -55   Max: -10.1
Current: -10.1
-55
-10.1
ยป ACHN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

ACHN Guru Trades in Q2 2012

George Soros Sold Out
Pioneer Investments 11,100 sh (-93.16%)
» More
Q3 2012

ACHN Guru Trades in Q3 2012

John Burbank 500,000 sh (New)
Steven Cohen 22,200 sh (New)
Pioneer Investments Sold Out
» More
Q4 2012

ACHN Guru Trades in Q4 2012

John Burbank Sold Out
Steven Cohen 12,145 sh (-45.29%)
» More
Q1 2013

ACHN Guru Trades in Q1 2013

Paul Tudor Jones 23,217 sh (New)
Steven Cohen Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ACHN

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Burbank 2012-12-31 Sold Out 0.24%$7.2 - $11.1 $ 7.77-12%0
John Burbank 2012-09-30 New Buy0.24%$5.61 - $10.41 $ 7.7710%500000
George Soros 2012-06-30 Sold Out 0.04%$5.94 - $10.95 $ 7.776%0
George Soros 2012-03-31 Reduce -50%0.09%$7.71 - $12.375 $ 7.77-19%250000
George Soros 2011-12-31 Add 2132.14%0.16%$4.01 - $8 $ 7.7726%500000
George Soros 2011-09-30 New Buy$4.63 - $8.31 $ 7.7722%22400
Premium More recent guru trades are included for Premium Members only!!

Ratios

vs
industry		 vs
history
P/B 8.63
ACHN's P/B is ranked lower than
70% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. ACHN: 8.63 )
ACHN' s 10-Year P/B Range
Min: 0.65   Max: 12.2
Current: 8.63
0.65
12.2
P/S 194.25
ACHN's P/S is ranked lower than
91% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 6.90 vs. ACHN: 194.25 )
ACHN' s 10-Year P/S Range
Min: 0.78   Max: 412.33
Current: 194.25
0.78
412.33
EV-to-EBIT -28.64
ACHN's EV-to-EBIT is ranked higher than
95% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 14.61 vs. ACHN: -28.64 )
ACHN' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -28.64
Shiller P/E 5.26
ACHN's Shiller P/E is ranked higher than
91% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. ACHN: 5.26 )
ACHN' s 10-Year Shiller P/E Range
Min: 4.69   Max: 6.61
Current: 5.26
4.69
6.61

Valuation & Return

vs
industry		 vs
history
Price/Net Cash 11
ACHN's Price/Net Cash is ranked higher than
87% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 8.80 vs. ACHN: 11 )
ACHN' s 10-Year Price/Net Cash Range
Min: 0.6   Max: 11.7
Current: 11
0.6
11.7
Price/Net Current Asset Value 836.8
ACHN's Price/Net Current Asset Value is ranked higher than
99% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 32.60 vs. ACHN: 836.8 )
ACHN' s 10-Year Price/Net Current Asset Value Range
Min: 3.3   Max: 801
Current: 836.8
3.3
801
Price/Tangible Book 8.7
ACHN's Price/Tangible Book is ranked higher than
86% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 4.70 vs. ACHN: 8.7 )
ACHN' s 10-Year Price/Tangible Book Range
Min: 0.5   Max: 77.8
Current: 8.7
0.5
77.8
Price/Median PS Value 1.7
ACHN's Price/Median PS Value is ranked higher than
92% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 0.90 vs. ACHN: 1.7 )
ACHN' s 10-Year Price/Median PS Value Range
Min: 0.1   Max: 1.6
Current: 1.7
0.1
1.6
Earnings Yield (Greenblatt) 286.10
ACHN's Earnings Yield (Greenblatt) is ranked higher than
95% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 8.00 vs. ACHN: 286.10 )
ACHN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.3   Max: 325.8
Current: 286.1
0.3
325.8
Forward Rate of Return (Yacktman) -41.16
ACHN's Forward Rate of Return (Yacktman) is ranked higher than
61% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -4.65 vs. ACHN: -41.16 )
ACHN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 44.6   Max: 45
Current: -41.16
44.6
45

Business Description

Achillion Pharmaceuticals, Inc. was incorporated in Delaware. It is a biopharmaceutical Company which focuses on the discovery, development and commercialization of innovative treatments for infectious diseases. Within the anti-infective market, it is currently concentrating on the development of antivirals for the treatment of chronic hepatitis C and the development of antibacterials for the treatment of resistant bacterial infections. It is currently focusing its efforts on advancing two late-stage preclinical candidates: ACH-1095, an NS4A antagonist for the treatment of chronic hepatitis C, being developed in collaboration with Gilead Sciences, Inc. (Gilead), and ACH-1625, a protease inhibitor also for the treatment of chronic hepatitis C. In addition, it has a pipeline of other product candidates for which it is currently seeking appropriate collaborative partners. These product candidates include elvucitabine for the treatment of HIV infection and ACH-702 for the treatment of serious bacterial infections. The company's industry is highly competitive and subject to rapid and significant technological change. All of the drugs it is developing, if approved, would compete against existing therapies.preclinical candidates: ACH-1095, an NS4A antagonist for the treatment of chronic hepatitis C, being developed in collaboration with Gilead Sciences, Inc. (Gilead), and ACH-1625, a protease inhibitor also for the treatment of chronic hepatitis C. In addition, it has a pipeline of other product candidates for which it is currently seeking appropriate collaborative partners. Its strategy is to pursue patents, developed internally and licensed from third parties, and other means to otherwise protect its technology, inventions and improvements that are commercially important to the development of its business. The Company is subject to federal, state and local laws.
Company Website
SEC Reports
Industry: Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG
Traded in other countries:ADA.Germany
ยป More Articles for ACHN

Headlines

Articles On GuruFocus.com
Weekly CEO Sells Highlight: Achillion Pharmaceuticals Inc, Monster Beverage Corp, CarMax Inc, and Im Jan 23 2012 
Weekly CEO Sells Highlight: UNH, LRY, ACHN, RPM Jan 16 2012 
Achillion Pharmaceuticals Inc. Reports Operating Results (10-Q) Oct 27 2010 
Achillion Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 13 2010 
Achillion Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 03 2009 
Achillion Pharmaceuticals Inc. Reports Operating Results (10-Q) May 15 2009 
David Swensen Buys American International Group Inc., Franklin Resources Inc., RightNow Technologies Feb 13 2008 

More From Our Partners
Achillion Names Dr. David Apelian CMO May 15 2013 - BENZINGA

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial